The Size of the Asia Pacific Animal Parasiticides Market is valued USD 2.44 billion in 2019 and expected to be growing at a CAGR of 5.9%, to reach USD 3.25 billion by 2024 during the forecast period 2019-2024.
The market shows evident growth potential in the mentioned forecasting period. It is expected to expand in the future years with the gradual increase in awareness about animal health.
Animal parasiticides are the medications intended for the removal of all the parasites other than fungi and bacteria present on animals. They are generally non-reactive chemical substances which are mixed with each other and may have many different ingredients. Ingredients in a parasiticide generally have uniform chemical structures and have some common features. Often they are categorized according to the chemical families they belong to. The animal parasiticides have high importance when it comes to protecting animals from parasitic diseases.
Rising pet population, Increasing the ability of people to spend on the healthcare of animals, growing concern for the quality of meat and animal products like leather and milk and the development in the R & D sector of animal healthcare have led to the growth of Asia-Pacific Animal Parasiticides market. However, growing inclination towards vegetarian and vegan lifestyles as well as strict restrictions on the approval for animal parasiticides are hindering the growth of the Asia-Pacific animal parasiticides market.
Asia Pacific Animal Parasiticides Market has been segmented and sub-segmented into the following categories
Noteworthy companies dominating the Asia Pacific animal parasiticides market profiled in the report are Sanofi S.A. (Merial), Ceva Sante Animale, Virbac SA, Vetoquinol S.A., Eli Lilly and Company, Zoetis Inc., Merck & Co Inc., Bayer AG, Boehringer Ingelheim GmbH and Perrigo Co. plc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Ectoparasiticides
5.1.3 Endoparasiticide
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 Animal Type
5.2.1 Introduction
5.2.2 Food-producing Animals
5.2.3 Companion Animals
5.2.4 Y-o-Y Growth Analysis, By Animal Type
5.2.5 Market Attractiveness Analysis, By Animal Type
5.2.6 Market Share Analysis, By Animal Type
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Animal Type
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Animal Type
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Animal Type
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Sanofi
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Ceva Sante Animale
8.3 Eli Lilly and Company
8.4 Zoetis Inc.
8.5 Merck and Co.
8.6 Bayer AG
8.7 Boehringer Ingelheim
8.8 Perrigo Company Plc
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
